TT
Gmp Manufacturing Scientist
Get the full picture
Sign in to uncover key details.
Sapu Bioscience
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10840 Thornmint Rd Ste 118, San Diego, C...Phone Number
(650) 635-7018Website
www.sapubio.comRevenue
<$5 MillionIndustry
About Sapu Bioscience
Sapu Bioscience is an immuno-oncology company focused on developing first-in-class RNA therapeutics and small molecule drugs targeting cancer and infectious diseases. Their lead candidate, OT-101, is an anti-TGF-β RNA therapeutic that has shown promise in treating relapsed/refractory cancer patients and has activity against SARS-CoV-2. The company aims to enhance treatment outcomes for cancer patients, particularly in rare pediatric cancers, and holds a rare pediatric designation for DIPG. With over 30 years of experience and more than 100 patent applications, Sapu Bioscience is positioned to make significant advancements in the field.Explore more
Sapu Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Sapu Bioscience
Compare insights from companies similar to Sapu Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sapu Bioscience Tech Stack
A closer look at the technologies used by Sapu Bioscience
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sapu Bioscience
Sign Up For FreeTo access detailed company insights
Sapu Bioscience is an immuno-oncology company focused on developing first-in-class RNA therapeutics and small molecule drugs targeting cancer and infectious diseases. Their lead candidate, OT-101, is an anti-TGF-β RNA therapeutic that has shown promise in treating relapsed/refractory cancer patients and has activity against SARS-CoV-2. The company... Read More
